Abivax SA
2X1
Company Profile
Business description
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
Contact
7-11 boulevard Haussmann
Paris75009
FRAT: +33 153830963
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
69
Stocks News & Analysis
stocks
Westpac earnings: Tech overhaul is costly but not hurting lending and deposit growth
Our view after latest earnings report.
stocks
Berkshire Hathaway earnings: Cash balances hit $358 billion on mostly solid results across the firm
We think Berkshire Hathaway stock is moderately undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,120.40 | 53.60 | -0.58% |
| CAC 40 | 8,109.79 | 11.28 | -0.14% |
| DAX 40 | 24,132.41 | 174.11 | 0.73% |
| Dow JONES (US) | 47,336.68 | 226.19 | -0.48% |
| FTSE 100 | 9,701.37 | 15.88 | -0.16% |
| HKSE | 26,195.92 | 37.56 | 0.14% |
| NASDAQ | 23,834.72 | 109.77 | 0.46% |
| Nikkei 225 | 52,446.08 | 34.74 | 0.07% |
| NZX 50 Index | 13,600.94 | 44.64 | 0.33% |
| S&P 500 | 6,851.97 | 11.77 | 0.17% |
| S&P/ASX 200 | 8,835.00 | 47.70 | -0.54% |
| SSE Composite Index | 3,974.08 | 2.45 | -0.06% |